

**Azucena Bardaji (Spain; MD – Family & Community Medicine, MSc Epidemiology; PhD – Public Health)**

- Research focus on impact of infectious disease during pregnancy as well as infant morbidity and mortality, and evaluation of preventative strategies; More recently focus is on maternal immunisation
- For Brighton, participated in the GAIA (Global Alignment of Immunization Safety Assessment in Pregnancy) project Working Groups for defining Low Birth Weight, Small for Gestational Age, and Congenital Microcephaly, Postpartum Endometritis, Chorioamnionitis as well as the Guidelines for Safety Data
- LMIC experience In Africa, South America, India and Papua New Guinea working on women's, children's and adolescent health programs
- Longstanding activities in Training PhD students as well as Lecturing in courses on global health epidemiology and maternal and reproductive health

**Jim Buttery (Australia; MD; Pediatric Infectious Disease specialist)**

- Brighton Science Board member (2011-2018)
- Head, Epidemiology and Signal Detection of SAEFIVIC – Immunisation Safety Service
- Global Vaccine Data Network – member of the executive
- Expert advisor to the PATH Advancing Maternal Immunization collaboration
- Member of WHO Strategic Priority Group – Global Vaccine Safety Initiative
- Member of WHO Global Advisory Committee on Vaccine Safety
- Australian Therapeutic Goods Administration (TGA) Advisory Committee on Vaccines (2017 – present)
- Victorian Immunisation Advisory Committee

**Clare Cutland (South Africa; Bachelor-Medicine/Surgery (MBBCh); Diploma in Child Health; PhD)**

- Scientific coordinator, African Leadership in Vaccinology Expertise (ALIVE) – 2018 to present (aim is to create African expertise and leadership in vaccinology training, research and advocacy); vaccine researcher at the University of Witwatersrand with a focus on maternal immunization and foetal/neonatal outcomes in Low and Middle Income country settings
- Member, Brighton Science Board since 2018.
- Lead for development of Brighton Case definitions for Neonatal death and Low Birth Weight and partook in WH for several other definitions as part of the GAIA project (Global Alignment of Immunisation Safety Assessment in Pregnancy)
- Extensive experience from 2002 to present with vaccine clinical trials, field-testing of BC (GAIA) definitions in LMICs, multi-country vaccine safety surveillance in Africa

**Alejandro Cravioto (Mexico; MD Pediatrics; DTPH, PhD University of London, UK)**

- Dean University of Mexico Medical School (1995—2003)
- Executive Director, International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh (2005-2012)

- Chief Scientific Officer, International Vaccine Institute, Seoul Korea (2012-2014)
- WHO Strategic Advisory Group of Experts on Immunization (Member 2015-17; Chair 2017 to present)
- Extensive research career with a focus on interaction between infection and growth in young infants and vaccine development to prevent pathogenic bacterial and viral diseases (including cholera, typhoid, polio, rotavirus and HPV)
- Member of Mexico's National Advisory Group on Vaccines and Technical Advisory Group for COVID-19 vaccines
- Involved in several Brighton Collaboration events related to maternal immunization
- Extensive Journal Editorial Board experience including Editor in Chief for the Journal of Health, Population and Nutrition (2007-12) and on the Editorial Board of BMC Tropical Diseases, Travel Medicine and Vaccines (2014-to date)

**Matthew Dudley (USA; PhD Global Disease Epi and Control, -Johns Hopkins Bloomberg School of Public Health)**

- Johns Hopkins Bloomberg School of Public Health, Institute for Vaccine Safety: Epidemiologist (Aug 2014-Oct 2020); Co-Director of Epidemiology (Nov 2020 to present)
- Research areas include vaccine safety, vaccine hesitancy, and vaccine communication
- Co-author for Brighton case definitions of Vaccine-associated enhanced disease, Sensorineural hearing loss; supported several other CD WGs and led efforts to set up a new Brighton 2.0 website under the umbrella of Task Force for Global Health
- Lead author on a Lancet Infect Dis 2020 article "The state of vaccine safety science: systematic reviews of the evidence" and a book "The Clinician's Vaccine Safety Resource Guide: Optimizing Prevention of Vaccine-Preventable Diseases Across the Lifespan".
- Conceptualized an individually tailored vaccine educational app called MomsTalkShots/LetsTalkShots and worked with technology companies to program, test and update it.

**Jane Gidudu (USA; MD; Epidemiologist; Masters Public Health)**

- Scientific coordinator for Brighton Collaboration (2004-6); continued engagement with Brighton Collaboration as team lead within the CDC Immunization Safety Office (2006-9); Led, and/or initiated or contributed to >20 Brighton case definitions, as well as guidelines for vaccine safety data collection in clinical trials in general, and for maternal/neonatal vaccine trials; worked on evaluation of several BC case definitions
- CDC Global Immunization Safety Team, leading multiple vaccine safety activities at global, regional and country level (2016 to present) including training for vaccine campaigns safety monitoring
- Associate Director for Science at CDC Immunization Safety Office (2009-2011); CDC lead for CISA Network Project (2011)
- Serves on regional advisory committee on vaccine safety (AFRO)
- Advisor on vaccine risk and benefits communication

**Hector Izurieta (USA; MD; MPH; PhD Epidemiology)**

- Past member of the Brighton Science Board and chaired it from 2014-6
- Food and Drug Administration (FDA) held a variety of positions from 2003 to current times including Chief, Analytical Epidemiology Branch, and since 2012 Epidemiologist designing/leading research studies on vaccine and biologics effectiveness and safety
- Pan American Health Organization (PAHO) - was acting chief of the PAHO Immunization Unit; before that an international advisor in their Division of Vaccines and Immunization
- Epidemic Intelligence Service Officer at the National Immunization Program, CDC
- International vaccine experience included 2 years with Medecins sans Frontieres in South Sudan; Medical advisor of Swiss-Benin Medical aid Program in Benin, West Africa
- Served as the FDA liaison for Health Canada's Advisory Committee on Causality Assessment (specific to vaccine-adverse event associations; 2004-7)
- Represented CBER (FDA Center for Biologics Research and Review) on the Mini-Sentinel Safety Science Committee (large linked databases used to identify vaccine safety signals)

#### **Najwa Khuri-Bulos (Jordan; MD Pediatric Infectious Disease)**

- Chairs Jordan Immunization Committee (since 1985)
- Founding director of the Infectious Disease and Vaccine Center, Univ. Jordan
- Longstanding contributor to Brighton Collaboration including past service as a member of the Science Board and membership several case definition WGs, guidelines for collection, analysis and presentation of vaccine safety data in clinical studies and surveillance systems; the Viral Vector Vaccine Safety Working Group and the GAIA project for immunization outcomes in pregnancy.
- Presented a paper to London School for Tropical Medicine and Hygiene on risk communication on vaccine adverse events; currently a science advisor for the Jordan Media Institute and involved in 'infodemic' issues related to COVID-19
- A Distinguished professor of Pediatric Infectious Disease at Jordan University and working on organizing vaccination online courses

#### **Wan-Ting Huang (Taiwan; MD Pediatric Infectious Disease)**

- Taiwan Center for Disease Control which operates National Immunization Program (2006-2020) and Chief Medical Officer (2016-2020)
- Active participant in multi-country collaborative vaccine safety research projects (Influenza Immunization and Narcolepsy Study, Global Vaccine Safety Data Network)
- Brighton Collaboration Science Board member since 2018
- Leads Quality assessment for the Brighton SPEAC (Safety Platform for Emergency vACcines) project (since 2019) and is a lead for Brighton/Task Force for Global Health active COVID vaccine safety surveillance

#### **Denny Kim (USA; MD – Preventive Medicine and Public Health specialty; MPH)**

- Extensive experience in clinical vaccine research and safety since 2007 with several vaccine developers
- Currently with Novavax as Chief Safety Officer and previously with Janssen (Johnson and Johnson) as Excellence Leader in vaccine safety

- Lead in HIV Vaccine trials for the HIV Vaccines Trials Network at Fred Hutchinson Cancer Research Center (2005-7)
- Member of the Brighton Viral Vector Vaccines Safety Working Group since 2014 and primary or co-author for 7 publications

**Nicola Klein (USA; MD Pediatric Infectious Disease)**

- Director Kaiser Permanente Vaccine Study Center, Oakland California (2016-present)
- Principal Investigator for the CDC – sponsored CISA Network and Vaccine Safety Datalink Project. Currently leading the VSD COVID-19 vaccines rapid cycle analysis to monitor vaccine safety in near real time.
- Principal investigator for both industry and federally-sponsored Phase 2 and 3 vaccine trials
- Research focus includes genetics of vaccine responses and vaccine safety among special populations
- Multiple awards for publication excellence (Outstanding Paper Award, Article of the Year and so on) relating to vaccine effectiveness and vaccine safety
- Member of several Brighton case definition WGs (neonatal, maternal, sensorineural hearing loss, MIS-C/A)

**Sonali Kochhar (India; MD Pharmacology)**

- Member and Co-Chair, Brighton Collaboration Science Board (2018 to present))
- Helped to set up the Gates Foundation funded Global Alignment of Immunization Safety Assessment in Pregnancy and helped in the development of 26 Brighton case definitions for Maternal and Neonatal adverse outcomes. Led the field testing and validation of the GAIA case definitions in LMIC
- Member of Viral Vector Vaccine Safety Working group (since 2014) and led the development of the five standardized template for the benefit-risk assessment of vaccines
- Primary or co-author of 38 Brighton Collaboration publications (including case definitions, template protocols, and guidelines for vaccine safety data collection)
- Member WHO Strategic Advisory Group of Experts on Immunization (SAGE) since 2021, and WHO SAGE Working Group on COVID-19 vaccines since 2020
- Extensive experience working in High and Low-Middle Income Countries on vaccine clinical research, safety, introduction of new vaccines, and increasing immunization coverage and acceptance
- Leading vaccine safety activities and capacity building at the global, regional, and national level for government partners, AEFI committees, healthcare workers, NITAGs and RITAGs
- Lead for Brighton/Task Force for Global Health to strengthen COVID-19 vaccine safety activities

**Paul Henri Lambert (Switzerland; MD – Internal Medicine; Immunologist)**

- Past positions as Head of multiple WHO Research Divisions (Hematology 1970-75; Immunology 1975-87; Vaccine research and Development within the WHO Global Programme for Vaccines and Immunizations(1994-9);
- Chaired the WHO Global Advisory Committee for Vaccine Safety (2005-2009)
- Director International Advanced Course of Vaccinology (ADVAC), Annecy, France (2000-2018)
- Senior Advisor, Centre of Vaccinology, University of Geneva (2003-present)
- Focus on research into the immunological mechanisms involved in autoimmune and immune complex disease (author or co-author of 474 publications and several books)
- Joined the Brighton science board in 2020 after the retirement of James Oleske

**Karina Top (Canada; MD – Pediatric Infectious Disease; Epidemiologist)**

- Leads vaccine safety efforts within the Canadian Immunization Research Network (CIRN)
- Principal investigator of the CIRN Special Immunization Clinic (SIC) Network which focuses on assessing vaccine safety and AEFI in individuals
- Co-lead with Dr. Robert Chen of the International Network of Special Immunization Services (INSIS) which is focusing on risk factors and mechanisms underlying rare AEFIs following COVID-19 vaccination
- Investigator for the Canadian Immunization Monitoring Program ACTIVE (IMPACT) which is an active pediatric hospital-based sentinel surveillance program (AEFIs and VPDs)
- Provides expert advice on vaccine safety to the Canadian NITAG – National Advisory committee on immunization (NACI)
- Member of the executive of the Canadian Association for Immunization Research, Evaluation and Education (CAIRE).
- WHO consultant to workshops on AEFI surveillance and causality assessment in European middle-income countries
- For Brighton has been a member of several Case Definition WGs

**Bob Wise (USA; MD – Preventive Medicine and Public Health; Clinical Pharmacology)**

- Food and Drug Administration (FDA; 1985-2011) – variety of positions as a medical pharmacoepidemiologist and Deputy Director Division of Epidemiology (2009-11)
- FDA lead for Brighton Thrombocytopenia Working group; also part of the WGs for Unexplained Sudden Death and the Guidelines for Safety data collection, analysis and presentation in clinical trial as well as pharmacovigilance settings
- Industry experience – Safety Medical Director (AstraZeneca/MedImmune – 2011-16)
- International Health residency with PAHO in Guatemala; consultations in West Africa for US Agency for International Development
- Sat on the management board for the MedDRA (Medical dictionary for Regulatory Activities) and on the Canadian Advisory Committee for Causality Assessment
- Retired in 2016 but acting as an Independent consultant, most recently providing medical epidemiologic consultations on COVID-19 pandemic

**Nicholas Wood (Australia; MD – Pediatrics; PhD with thesis on Vaccination in the newborn period)**

- Current member of the Brighton Science Board (since 2018)
- Leads New South Wales Immunisation Specialist service and coordinates the Immunisation Adverse Events Clinic at Westmead Children's Hospital
- Clinical lead for Australia's active vaccine surveillance system (AusVax Safety)
- Associate Director Clinical Research, National Centre for Immunization Research and Surveillance, Sydney, Australia
- Clinical Lead of the Paediatric Active Enhanced Diseases Surveillance (PAEDS) program in Australia
- Areas of research focus include maternal and neonatal immunisation and vaccine safety in particular genetics and long-term outcomes of AEFI
- Investigator on industry and academic vaccine trials – including an candidate COVID-19 DNA vaccine
- Member of the Brighton Collaboration Diarrhea case definition working group
- International experience with Medecins Sans Frontiers in China (activity included immunisation program) and South Sudan;